SA PRO
Free Account
Neumora Therapeutics, Inc. Common StockNMRANASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
8 analysts·Limited coverage
63%
Rating Distribution
Strong Buy
00%
Buy
563%
Hold
113%
Sell
225%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 266% higher.

Bear Case
$6.00
+203%
Consensus
$7.25
+266%
Bull Case
$8.00
+304%
Price Range8 analysts
Low
Consensus
High
$6.00
$8.00
Current Target
Current Price
$1.98
Upside to Target
$5.27

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 12, 2026Leerink Partners
Neumora Therapeutics initiated with an Outperform at Leerink
Target:$8.00
+252.4%from $2.27
Jan 5, 2026Mizuho Securities
Neumora Therapeutics (NMRA) PT Raised to $6 at Mizuho
Target:$6.00
+248.8%from $1.72
Dec 1, 2025RBC Capital
Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital
Target:$7.00
+212.5%from $2.24
Oct 28, 2025Needham
Neumora Therapeutics price target raised to $8 from $6 at Needham
Target:$8.00
+208.3%from $2.60
Mar 7, 2025Stifel Nicolaus
Neumora Therapeutics downgraded to Hold from Buy at Stifel
Target:$2.00
+34.2%from $1.49
Jan 2, 2025RBC Capital
RBC Capital Downgrades Neumora Therapeutics (NMRA) to Sector Perform
Target:$4.00
+103.0%from $1.97
Jul 22, 2024Needham
Neumora Therapeutics initiated with a Buy at Needham
Target:$23.00
+103.9%from $11.28
Jul 8, 2024Mizuho Securities
Neumora Therapeutics initiated with an Outperform at Mizuho
Target:$20.00
+95.1%from $10.25
Jun 17, 2024RBC Capital
RBC Capital Reiterates Outperform Rating on Neumora Therapeutics (NMRA)
Target:$29.00
+198.7%from $9.71
Mar 13, 2024RBC Capital
RBC Capital Out Positive on Neumora Therapeutics (NMRA): ' See Compelling Entry Point Ahead of Key 2H24 Catalysts'
Target:$31.00
+109.3%from $14.81
Oct 10, 2023Stifel Nicolaus
Why Neumora Therapeutics Analysts Are Bullish About Major Depressive Disorder Drug
Target:$26.00
+138.3%from $10.91
Oct 10, 2023RBC Capital
Why Neumora Therapeutics Analysts Are Bullish About Major Depressive Disorder Drug
Target:$24.00
+120.0%from $10.91

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance